Compare COHN & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | IMA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 54.8M |
| IPO Year | 2003 | N/A |
| Metric | COHN | IMA |
|---|---|---|
| Price | $15.67 | $5.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 30.0K | ★ 384.9K |
| Earning Date | 05-01-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | N/A |
| EPS | ★ 4.35 | N/A |
| Revenue | ★ $275,564,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.32 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $7.78 | $3.94 |
| 52 Week High | $32.60 | $17.50 |
| Indicator | COHN | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 51.06 |
| Support Level | $10.33 | $5.52 |
| Resistance Level | $16.48 | $7.17 |
| Average True Range (ATR) | 1.94 | 0.40 |
| MACD | -0.65 | 0.03 |
| Stochastic Oscillator | 0.00 | 35.41 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.